



19.9.2024

## **PBM Medical Technologies LTD: Transforming Vision Care and AMD Prevention**

**Photobiomodulation (PBM)**, also known as low-level light therapy, is an emerging effective therapeutic modality with a proven potential to manage a variety of ocular conditions.

At **PBM Medical Technologies Ltd**, our first mission is to provide non-invasive, accessible solutions for **Dry Age-Related Macular Degeneration (dry-AMD)**, the leading cause of blindness in individuals over 65. AMD is an eye condition that primarily affects the **macula**, the central part of the retina responsible for sharp vision. As the condition progresses, the macula gradually thins and loses its function, resulting in blurry or distorted central vision and, potential blindness.

Today, over **196 million people worldwide** suffer from various stages of dry AMD, an underserved market where current treatments offer limited effectiveness. **Vitamins**, like those in the AREDS2 formula, can help slow progression in certain patients but do not halt or reverse the disease. Two new drugs, injected regularly into the eye slow the development of certain types of dry AMD by up to 20%, they do not improve vision and are causing severe side effects in many patients. Recently, new in-clinic PBM treatments with established medical protocols have emerged to aid AMD patients and are close to receiving FDA approval; however, these options are expensive and impose additional burdens on healthcare systems and patients due to the necessary repeated clinic visits and overall costs. By contrast, our solution which utilizes the same PBM treatment offers a scalable and affordable home-based alternative, effectively addressing critical gaps in both cost and accessibility, and providing a practical approach for the long-term management of dry AMD.

The global AMD market (both dry and wet) is projected to grow to \$18 billion by 2030, driven by aging populations and rising healthcare demands. In the U.S. alone, 15-20 million people suffer from dry AMD, with the market for treatments valued at approximately \$2.64 billion in 2024, expected to grow as the population ages and more patients seek treatment. Our future strategic goal is to expand into early detection and prevention, allowing us to capture a significant share of the broader AMD market.

Our solution **SightRetain®** goggles (**\*patent pending**) delivers a precise light at three specific wavelengths, similar to those to be approved by the FDA, to stimulate cellular repair in the retina . Our light therapy technology is based on Light-Emitting Diodes (LEDs) in the visible and near-infrared spectrum (600-1000nm). This light penetrates the retina and is absorbed by cells, interacting with chromophores and enzymes to trigger photophysical and photochemical changes. These changes promote healing and cellular repair at the molecular, cellular, and tissue levels, making it a promising treatment for dry AMD.

Our experienced team, composed of top executives, PhD specializing in PBM and leading ophthalmologists together with our impressive advisory board which include Prof. Belkin, brings the capabilities and expertise necessary to navigate this journey successfully.

Our go-to-market strategy focus start with the US market, securing a billing code for insurance reimbursement and partnering with ophthalmologists and healthcare providers to drive adoption.

Our device will be available by prescription, and our strategic partnerships will accelerate its integration into clinical practice.

We are in the process of capital raising to secure the FDA 510K approval, mirroring successful clinic-based PBM regulatory strategies to minimize risk and expedite market entry. These funds will also support enhancements in product engineering and bolster our efforts to scale commercialization. This investment will cover the costs associated with regulatory approval, product development enhancements, and the necessary infrastructure for early market entry.

**This is your opportunity to invest in the future of AMD treatment and prevention, providing groundbreaking solutions that will redefine how millions of patients manage their vision health with potential uses in other eye and body diseases.**



---

SightRetain® -The company's technology has been submitted for a patent application in the USA and is currently undergoing the PCT process under application number PCT/IL2024/050579, titled "PHOTOTHERAPEUTIC EYEWEAR DEVICE."

**For more Details contact us:**

Ronen Berger

+972-542872577

[ronen@pbm-medical.com](mailto:ronen@pbm-medical.com)